Ofatumumab for treating chronic lymphocytic leukemia: A safety profile

Expert Opinion on Drug Safety

Volumn 14, Issue 12, 2015, Pages 1945-1959

  Korycka Wołowiec, Anna ^a   Wołowiec, Dariusz ^b   Robak, Tadeusz ^a  

^a MEDICAL UNIVERSITY OF LODZ   (Poland)

^b WROCLAW MEDICAL UNIVERSITY   (Poland)

Author keywords

chronic lymphocytic leukemia; clinical efficacy; monoclonal antibody; ofatumumab; safety profile

Indexed keywords

OFATUMUMAB; RITUXIMAB; ANTINEOPLASTIC AGENT; CD20 ANTIGEN; MONOCLONAL ANTIBODY;

ADVERSE OUTCOME; AREA UNDER THE CURVE; CANCER IMMUNOTHERAPY; CHRONIC LYMPHATIC LEUKEMIA; COMPLEMENT DEPENDENT CYTOTOXICITY; DRUG ACTIVITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG HALF LIFE; DRUG INDUCED DISEASE; DRUG MECHANISM; DRUG METABOLISM; DRUG SAFETY; DRUG STRUCTURE; DRUG TOLERABILITY; FOLLOW UP; HEMATOLOGIC DISEASE; HUMAN; INFUSION RELATED REACTION; LEUKEMIA REMISSION; MAINTENANCE THERAPY; MAXIMUM PLASMA CONCENTRATION; MEDICAL SOCIETY; MINIMAL RESIDUAL DISEASE; MONOTHERAPY; NONHEMATOLOGICAL TOXICITY; PLASMA CONCENTRATION-TIME CURVE; QUALITY OF LIFE; REVIEW; TIME TO MAXIMUM PLASMA CONCENTRATION; TREATMENT DURATION; TREATMENT RESPONSE; VOLUME OF DISTRIBUTION; COMPARATIVE STUDY; IMMUNOLOGY; IMMUNOTHERAPY; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; PATHOLOGY; PROCEDURES; SALVAGE THERAPY;

ANTIBODIES, MONOCLONAL; ANTIGENS, CD20; ANTINEOPLASTIC AGENTS; HUMANS; IMMUNOTHERAPY; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; RITUXIMAB; SALVAGE THERAPY;

EID: 84951909067     PISSN: 14740338     EISSN: 1744764X     Source Type: Journal    
DOI: 10.1517/14740338.2015.1113253     Document Type: Review

References (57)

1. Leget GA, Czuczman MS. Use of rituximab, the new FDA-Approved antibody. Curr Opin Oncol. 1998; 10:548-551
2. Keating MJ, OBrien S, Robertson L, et al. Chronic lymphocytic leukemia-correlation of response and survival. Leuk Lymphoma. 1993;11(Suppl 2):167-175
3. Cheson BD. Monoclonal antibody therapy of chronic lymphocytic leukemia. Best Pract Res Clin Hematol. 2010;23:133-143
4. Gribben JG, OBrien S. Update on therapy of chronic lymphocytic leukemia. J Clin Oncol. 2011;29:544-550
5. McLaughlin P, Grillo-Lpez AJ, Link BK, et al. Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program. J Clin Oncol. 1998;16: 2825-2833
6. OBrien S, Ostenborg A. Ofatumumab: A new CD20 monoclonal antibody therapy for B-cell chronic lymphocytic leukemia. Clin Lymphoma Myeloma Leuk. 2010;10:361-368
7. Molica S. Progress in the treatment of chronic lymphocytic leukemia: results of the German CLL8 trial. Expert Rev Anticancer Ther. 2011;11:1333-1340
8. Hallek M, Fischer K, Fingerle-Rowson G, et al. Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukemia: A randomized, open label, phase 3 trial. Lancet. 2010;376:1164-1174
9. Seiter K, Mamorska-Dyga A. Obinutuzumab treatment in the elderly patient with chronic lymphocytic leukemia. Clin Interv Aging. 2015;10:951-961
10. Barth MJ, Czuczman MS. Ofatumumab: A novel, fully human anti-CD20 monoclonal antibody for the treatment of chronic lymphocytic leukemia. Future Oncol. 2013;9:1829-1839
11. Reagan JL, Castillo JJ. Ofatumumab as front-line therapy in untreated chronic lymphocytic leukemia. Future Oncol. 2014;10:1147-1155
12. Jaglowski SM, Alinari L, Lapalombella R, et al. The clinical application of monoclonal antibodies in chronic lymphocytic leukemia. Blood. 2010;116:3705-3714
13. Lemery SJ, Zhng J, Rothmann MD, et al. US Food and Drug Administration approval: ofatumumab for the treatment of patients with chronic lymphocytic leukemia refractory to fludarabine and alemtuzumab. Clin Cancer Res. 2010;16:4331-4338
14. Gravanis I, Ersboll J, Skovlund E, et al. The European medicines agency review of ofatumumab (Arzerra) for the treatment of chronic lymphocytic leukemia in patients refractory to fludarabine and alemtuzumab: summary of the scientific assessment of the European medicines agency committee for medicinal products for human use. Oncologist. 2010;15:1335-1343
15. FDA Grants Full Approval to Ofatumumab (Arzerra) for CLL [Internet]. 2014 [cited 2014 Apr 23]. Available from: www.cancer.gov/aboutcancer/treatment/drugs/fda-ofatumumab.
16. Cragg MS, Walshe CA, Ivanov AO, et al. The biology of CD20 and its potential as a target for mAb therapy. Curr Dir Autoimmun. 2005;8:140-174
17. Polyak MJ, Tailor SH, Deans JP. Identification of a cytoplasmic region of CD20 required for its redistribution to a detergent-insoluble membrane compartment. J Immunol. 1998;161:3242-3248
18. Teeling JL, French RR, Cragg MS, et al. Characterization of new human CD20 monoclonal antibodies with potent cytolytic activity against non-Hodgkin lymphomas. Blood. 2004;104:1793-1800
19. Davis TA, Czerwinski DK, Levy R. Therapy of B-cell lymphoma with anti-CD20 antibodies can result in the loss of CD20 antigen expression. Clin Cancer Res. 1999;5:611-615
20. Beers SA, Chan CHT, French RR, et al. CD20 as a target for therapeutic type I and II monoclonal antibodies. Semin Hematol. 2010;47:107-114
21. Weiner GJ. Rituximab: mechanism of action. Semin Hematol. 2010;47: 115-123
22. Ogura M, Hatake K, Tobinai K, et al. Phase I study of ofatumumab, a human anti-CD20 antibody, in Japanese patients with relapsed or refractory chronic lymphocytic leukemia and small lymphocytic lymphoma. Jpn J Clin Oncol. 2013;43:466-475
23. Dua J, Yanga H, Guo Y, et al. Structure of the Fab fragment of therapeutic antibody ofatumumab provides insights into the recognition mechanism with CD20. Molecular Immunol. 2015;46:2419-2423
24. Beum PV, Lindorfer MA, Beurskens F, et al. Complement activation on B lymphocytes opsonized with rituximab or ofatumumab produces substantial changes in membrane structure preceding cell lysis. J Immunol. 2008;181:822-832
25. Mamidi S, Hne S, Teufel C, et al. Neutralization of membrane complement regulators improves complement-dependent effector functions of therapeutic anticancer antibodies targeting leukemic cells. Oncoimmunology. 2015;4:e979688
26. Osterborg A, Udvardy M, Zariteskey A, et al. Ofatumumab (OFA) vs physician choice (PC) of therapy in patients (pts) with bulky fludarabine-refractory (BFR) chronic lymphocytic leukemia (CLL): results of the phase III study OMB114242. Blood. 2014;124 (abstract):4684
27. Osterborg A, Jewell RC, Padmanabhan-Iyer S, et al. Ofatumumab monotherapy in fludarabine-refractory chronic lymphocytic leukemia: final results from a pivotal study. Haematologica. 2015;100:311-314
28. Coiffier B, Lepretre S, Pedersen LM, et al. Safety and efficacy of ofatumumab, a fully human monoclonal anti-CD20 antibody, in patients with relapsed or refractory B-cell chronic lymphocytic leukemia: A phase 1-2 study. Blood. 2008;111: 1094-1100
29. Coiffier B, Losic N, Ronn BB, et al. Pharmacokinetics and pharmacodynamics association of ofatumumab, a human monoclonal CD20 antibody in patients with relapsed or refractory chronic lymphocytic leukemia: A phase 1-2 study. Br J Haematol. 2010;150:58-71
30. Keizer RJ, Huitema ADR, Schellens JHM, et al. Clinical pharmacokinetics of therapeutic monoclonal antibodies. Clin Parmacokinet. 2010;49:493-507
31. Mellman I, Plutner H. Internalization and degradation of macrophage Fc receptors bound to polyvalent immune complexes. J Cell Biol. 1984;98:1170-1177
32. Struemper H, Sale M, Patel BR, et al. Population pharmacokinetics of ofatumumab in patients with chronic lymphocytic leukemia, follicular lymphoma, and rheumatoid arthritis. J Clin Pharmacol. 2014;54:818-827
33. Bologna L, Gotti E, Da Roit R, et al. Ofatumumab is more efficient than rituximab in lysing B chronic lymphocytic leukemia cells in whole blood and in combination with chemotherapy. J Immunol. 2013;190:231-239
34. Wierda WG, Kipps TJ, Mayer J, et al. Ofatumumab as single-Agent CD20 immunotherapy in fludarabine-refractory chronic lymphocytic leukemia. J Clin Oncol. 2010;28:1749-1755
35. Wierda WG, Padmanabhan S, Chan GW, et al. Ofatumumab is active in patients with fludarabine-refractory CLL irrespective of prior rituximab: results from the phase 2 international study. Blood. 2011;118:5126-5129
36. Patton WN, Lindeman R, Butler AC, et al. An open-label, single-Arm, phase 1 study to assess biomarker effects, efficacy, and safety of ofatumumab in patients with refractory chronic lymphocytic leukemia. Leuk Lymphoma. 2015: 1-7. DOI:10.3109/10428194.2015.1014357
37. Byrd JC, Brown JR, OBrien S, et al. Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia. N Engl J Med. 2014;371:213-223
38. Dupuis J, Brice P, Francois S, et al. Ofatumumab in refractory chronic lymphocytic leukemia: experience through the French early access program. Clin Lymphoma Myeloma Leuk. 2015;15:43-46
39. Moreno C, Montillo M, Panayiotidis P, et al. Ofatumumab in poor-prognosis chronic lymphocytic leukemia: A phase IV, non-interventional, observational study from the European Research Initiative on Chronic Lymphocytic Leukemia. Heamatologica. 2015;100:511-516
40. van Oers MHJ, Kuliczkowski K, Smolej L, et al. Ofatumumab (OFA) maintenance prolongs PFS in relapsed CLL: prolong study interim analysis results. Blood. 2014;124(abstract):21
41. Ma S, Rosen ST, Frankfurt O, et al. A phase 2 study of alemtuzumab-ofatumumab (A+O) combination in patients with previously untreated chronic lymphocytic leukemia (CLL). Blood. 2014;124 (abstract):4686
42. Shanafelt T, Lanasa MC, Call TG, et al. Ofatumumab-based chemoimmunotherapy is effective and well tolerated in patients with previously untreated chronic lymphocytic leukemia (CLL). Cancer. 2013;119:3788-3796
43. Kay NE, Geyer SM, Call TG, et al. Combination chemoimmunotherapy with pentostatin, cyclophosphamide, and rituximab shows significant clinical activity with low accompanying toxicity in previously untreated B chronic lymphocytic leukemia. Blood. 2007;109:405-411
44. Wierda WG, Kipps T, Durig J, et al. Chemotherapy with O-FC in previously untreated patients with chronic lymphocytic leukemia. Blood. 2011;117: 6450-6458
45. Hillmen P, Robak T, Janssens A, et al. Chlorabmucil plus ofatumumab versus chlorambucil alone in previously untreated patients with chronic lymphocytic leukaemia (COMPLEMENT 1): A randomised, multicentre, open-label phase 3 trial. Lancet. 2015;385:1873-1883
46. Cortelezzi A, Sciume M, Liberati AM, et al. Bendamustine in combination with ofatumumab in relapsed or refractory chronic lymphocytic leukemia: A GIMEMA multicenter phase II trial. Leukemia. 2014;28:642-648
47. Jaglowski SM, Jones JA, Nagar V, et al. Safety and activity of BTK inhibitor ibrutinib combined with ofatumumab in chronic lymphocytic leukemia: A phase 1b/2 study. Blood. 2015;126:842-850
48. Doubek M, Brychtova Y, Panovska A, et al. Ofatumumab added to dexamethasone in patients with relapsed or refractory chronic lymphocytic leukemia: results from a phase II study. Am J Hematol. 2015;90:417-421
49. Robak T, Grosiki S, Warzocha K, et al. Ofatumumab (O) in combination with fludarabine (F) and cyclophosphamide (C) (OFC) vs. FC in patients with relapsed chronic lymphocytic leukaemia (CLL): results of the phase iii study COMPLEMENT 2 (OMB110913). Haematologica. 2015;100(abstract): LB219
50. Uppenkamp M, Engert A, Diehl V, et al. Monoclonal antibody therapy with CAMPATH-1H in patients with relapsed high-And low-grade non-Hodgkins lymphomas: A multicenter phase I/II study. Ann Hematol. 2002;81:26-32
51. Dyer MJS. Safety and efficacy of ofatumumab in patients with fludarabine and alemtuzumab refractory chronic lymphocytic leukemia. Adv Heamtol. 2012;3:199-207
52. van Oers MH, Kuliczkowski K, Smolej L, et al. Ofatumumab maintenance versus observation in relapsed chronic lymphocytic leukaemia (PROLONG): An open-label, multicentre, randomised phase 3 study. Lancet Oncol. 2015;16:1370-1379
53. Montillo M, OBrien S, Tedeschi A, et al. Autoimmune hemolytic anemia and immune mediated thrombocytopenia in the phase III RESONATETM study of ibrutinib vs ofatumumab in relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma, including a case report. Blood. 2014;124 (abstract):5654
54. Nader K, Patel M, Ferber A. Ofatumumab in rituximab-refractory autoimmune hemolytic anemia associated with chronic lymphocytic leukemia: A case report and review of literature. Clin Lymph Myeloma Leuk. 2013;13:511-513
55. Eyre T, Clifford R, Roberts C, et al. Single arm NCRI phase II study of CHOP in combination with ofatumumab in induction and maintenance for patients with newly diagnosed Richters syndrome. Cancer. 2015. DOI:10.1186/s12885-015-1048-9
56. Barrientos J, OBrien S, Brown JR, et al. Hematologic and immunologic function and patient well-being for the phase III RESONATETM study of ibrutinib vs ofatumumab in relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma. Blood. 2014;124 (abstract):4696
57. Product Monograph: Arzerra (ofatumumab). GlaxoSmithKline Inc. [revision 2014 Oct 2]. Available from: www.gsk.ca/english/docs-pdf/product-monographs/Arzerra.pdf